Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Multi-center Study to Evaluate the Safety, Efficacy, and Plasma Gadolinium Concentrations After an Intravenous Injection of 0.1 mL/kg Body Weight Eovist/Primovist for Enhanced Magnetic Resonance Imaging (MRI) of the Liver in Children 0 to 2 Months of Age

NCT02084628 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02084628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02084628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Multi-center Study to Evaluate the Safety, Efficacy, and Plasma Gadolinium Concentrations After an Intravenous Injection of 0.1 mL/kg Body Weight Eovist/Primovist for Enhanced Magnetic Resonance Imaging (MRI) of the Liver in Children 0 to 2 Months of Age
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2015
Completion date
August 31, 2015
Enrollment
1 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

magnetic resonance imaging